SELLAS Life Sciences Group, Inc.
SLS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001390478
No open-market purchases or sales by SELLAS Life Sciences Group, Inc. insiders were filed in the last 90 days; 193 institutions reported holding it in 13F filings for Q2 2026, worth $1.08B in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding SELLAS Life Sciences Group, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 25 | 28 | +3 |
| Shares | 3.13M | 2.77M | −359.7K (−11.5%) |
| Value | $4.91M | $4.54M | −$370.4K (−7.5%) |
New holders (5)
Institutions that held SELLAS Life Sciences Group, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| XTX Topco Ltd | 32,982 | $54.1K | 0.01% |
| Virtu Financial LLC | 18,962 | $31.0K | 0.00% |
| Jane Street Group, LLC | 11,032 | $18.1K | 0.00% |
| UBS Group AG | 26 | $43 | 0.00% |
| Qube Research & Technologies Ltd | 2 | $3 | 0.00% |
Sold out (2)
Institutions that held SELLAS Life Sciences Group, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Citadel Advisors LLC | 3,162 | $4.96K |
| NewSquare Capital LLC | 100 | $157 |